Weekly Cardiology Research Analysis
This week featured high-impact randomized and mechanistic cardiology studies that may influence practice and drug development. A multicenter RCT (HeartSync-LBBP) showed left bundle-branch pacing reduced the composite of death or heart-failure hospitalization versus biventricular pacing in HFrEF with LBBB. Mechanistic work (Nature Communications) identified Dlat-driven mitochondrial protein hyperacetylation as a targetable driver of HFpEF, and translational studies (Signal Transduction and Target
Summary
This week featured high-impact randomized and mechanistic cardiology studies that may influence practice and drug development. A multicenter RCT (HeartSync-LBBP) showed left bundle-branch pacing reduced the composite of death or heart-failure hospitalization versus biventricular pacing in HFrEF with LBBB. Mechanistic work (Nature Communications) identified Dlat-driven mitochondrial protein hyperacetylation as a targetable driver of HFpEF, and translational studies (Signal Transduction and Targeted Therapy) nominated sGC–PKG–ULK1 activation (vericiguat) to limit aortic valve calcification. Together these reports highlight shifts toward precise device selection, mitochondrial/metabolic therapeutic targets, and repurposing of cardiometabolic drugs for structural heart disease.
Selected Articles
1. Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial.
In a multicenter randomized trial of 200 patients with HFrEF and LBBB, left bundle-branch pacing (LBBP) reduced the composite of all-cause death or heart failure hospitalization versus biventricular pacing over a median 36 months (8% vs 28%; HR 0.26). HF hospitalizations were markedly lower and super-response rates higher with LBBP, though all-cause mortality alone did not differ significantly.
Impact: A high-quality randomized clinical trial providing compelling comparative-effectiveness data that could change CRT practice by supporting conduction system pacing in selected HFrEF with LBBB patients.
Clinical Implications: Clinicians and Heart Teams should consider LBBP as a potential first-line CRT strategy for HFrEF with LBBB where operator expertise exists, while balancing the need for confirmatory multinational trials and individualized patient selection.
Key Findings
- Randomized multicenter trial (n=200) with median 36-month follow-up.
- Primary composite (all-cause death or HF hospitalization) lower with LBBP vs BiVP (8% vs 28%; HR 0.26).
- HF hospitalization and super-response (LVEF increase ≥15% or to ≥50%) favored LBBP.
2. Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart.
Preclinical mechanistic work identifies Dlat as a mitochondrial transacetylase that hyperacetylates FAO proteins (notably HADHA K728), inhibiting fatty acid oxidation and driving HFpEF phenotypes. Genetic modulation of Dlat bidirectionally altered FAO, lipid metabolism, and HFpEF features, nominating mitochondrial acetylation and Dlat as targetable pathways.
Impact: Provides a concrete, previously unrecognized molecular mechanism linking metabolism to HFpEF and yields a druggable target (Dlat/acetylation), addressing a major unmet need for disease-modifying HFpEF therapies.
Clinical Implications: Translational priorities include validating the Dlat–HADHA acetylation axis in human HFpEF tissue, developing selective Dlat inhibitors or acetylation modulators, and conducting early-phase trials to test FAO restoration strategies.
Key Findings
- HFpEF hearts show mitochondrial protein hyperacetylation enriched in FAO pathway.
- Dlat identified as key mitochondrial transacetylase; Dlat acetylates HADHA at K728, inactivating enzymatic activity.
- Dlat overexpression worsens FAO and HFpEF phenotypes; knockdown rescues them.
3. Cyclic guanosine monophosphate-protein kinase G signaling attenuates aortic valve calcification through ULK1-mediated autophagy.
Translational studies integrating human valve tissue, genetic mouse models, ex vivo valve culture, and VIC assays show reduced cGMP–PKG signaling in calcified valves. Pharmacologic sGC/PKG activation (vericiguat > BNP ≈ sildenafil) phosphorylated ULK1 (Ser556), enhanced autophagy, preserved mitochondrial function, and reduced VIC osteogenic differentiation and leaflet calcification in models.
Impact: Identifies a mechanistic PKG–ULK1–autophagy axis linking mitochondrial homeostasis and valve calcification and proposes vericiguat (an sGC stimulator) as a repurposable therapeutic candidate for CAVD—an area lacking medical therapies.
Clinical Implications: Prioritize early-phase clinical trials of sGC stimulators (e.g., vericiguat) in CAVD with imaging endpoints and cGMP pharmacodynamic markers; consider biomarker-guided patient selection and monitoring.
Key Findings
- Human calcified valves show suppressed cGMP–PKG signaling and serum cGMP inversely correlates with calcification severity.
- PKGI haploinsufficiency worsens valve calcification in mice; pharmacologic activation (vericiguat most potent) reduces VIC calcification.
- PKG phosphorylates ULK1 (Ser556) to enhance autophagic flux, preserve mitochondria, and reduce inflammation/oxidative stress.